BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holleran G, Lopetuso L, Petito V, Graziani C, Ianiro G, McNamara D, Gasbarrini A, Scaldaferri F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int J Mol Sci. 2017;18. [PMID: 28934123 DOI: 10.3390/ijms18102020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu Y, Wu B, Zhang Z, Lu H, Fan C, Qi Q, Gao Y, Li H, Feng C, Zuo J, Tang W. Heme protects intestinal mucosal barrier in DSS-induced colitis through regulating macrophage polarization in both HO-1-dependent and HO-1-independent way. FASEB J 2020;34:8028-43. [PMID: 32301543 DOI: 10.1096/fj.202000313RR] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
2 Duncan VE, Chisholm KM, Pacheco MC. Effects of Tumor Necrosis Factor Alpha Inhibitors on Lymph Node and Ileocecal Mucosa-Associated Lymphoid Tissue Architecture in Patients With Inflammatory Bowel Disease. Pediatr Dev Pathol 2020;23:115-20. [DOI: 10.1177/1093526619866371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Li LL, Yuan HL, Yang YQ, Wang L, Zou RC. A brief review concerning Chimeric Antigen Receptors T cell therapy. J Cancer 2020;11:5424-31. [PMID: 32742489 DOI: 10.7150/jca.46308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Dovrolis N, Filidou E, Kolios G. Systems biology in inflammatory bowel diseases: on the way to precision medicine. Ann Gastroenterol 2019;32:233-46. [PMID: 31040620 DOI: 10.20524/aog.2019.0373] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Gurung P, Dahal S, Chaudhary P, Guragain D, Karmacharya U, Kim JA, Jeong BS. Potent Inhibitory Effect of BJ-3105, a 6-Alkoxypyridin-3-ol Derivative, on Murine Colitis Is Mediated by Activating AMPK and Inhibiting NOX. Int J Mol Sci 2020;21:E3145. [PMID: 32365634 DOI: 10.3390/ijms21093145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Silva NV, Carregosa D, Gonçalves C, Vieira OV, Nunes Dos Santos C, Jacinto A, Crespo CL. A Dietary Cholesterol-Based Intestinal Inflammation Assay for Improving Drug-Discovery on Inflammatory Bowel Diseases. Front Cell Dev Biol 2021;9:674749. [PMID: 34150769 DOI: 10.3389/fcell.2021.674749] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lu Q, Yang M, Liang Y, Xu J, Xu H, Nie Y, Wang L, Yao J, Li D. Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics. JIR 2022;Volume 15:1825-44. [DOI: 10.2147/jir.s353038] [Reference Citation Analysis]
8 Liu F, Li D, Wang X, Cui Y, Li X. Polyphenols intervention is an effective strategy to ameliorate inflammatory bowel disease: a systematic review and meta-analysis. Int J Food Sci Nutr 2021;72:14-25. [PMID: 32369394 DOI: 10.1080/09637486.2020.1760220] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Gao J, Cui J, Zhong H, Li Y, Liu W, Jiao C, Gao J, Jiang C, Guo W, Xu Q. Andrographolide sulfonate ameliorates chronic colitis induced by TNBS in mice via decreasing inflammation and fibrosis. Int Immunopharmacol 2020;83:106426. [PMID: 32220806 DOI: 10.1016/j.intimp.2020.106426] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Chen R, Tie Y, Lu J, Li L, Zeng Z, Chen M, Zhang S. Tripartite motif family proteins in inflammatory bowel disease: Mechanisms and potential for interventions. Cell Prolif 2022;:e13222. [PMID: 35373402 DOI: 10.1111/cpr.13222] [Reference Citation Analysis]
11 Cheon HJ, Nam SH, Kim JK. Tussilagone, a major active component in Tussilago farfara, ameliorates inflammatory responses in dextran sulphate sodium-induced murine colitis. Chem Biol Interact 2018;294:74-80. [PMID: 30142311 DOI: 10.1016/j.cbi.2018.08.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
12 Pippis EJ, Yacyshyn BR. Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. Inflamm Bowel Dis 2021;27:1674-83. [PMID: 33295611 DOI: 10.1093/ibd/izaa318] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bording-jorgensen M, Armstrong H, Wickenberg M, Lapointe P, Wine E. Macrophages and Epithelial Cells Mutually Interact through NLRP3 to Clear Infection and Enhance the Gastrointestinal Barrier. Immuno 2022;2:13-25. [DOI: 10.3390/immuno2010002] [Reference Citation Analysis]
14 Elewaut D, Braun J, Anderson JK, Arikan D, Chen S, Hojnik M, De Craemer AS, Curtis JR. Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. Arthritis Care Res (Hoboken) 2021;73:289-95. [PMID: 32100944 DOI: 10.1002/acr.24175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Andreou NP, Legaki E, Dovrolis N, Boyanov N, Georgiou K, Gkouskou K, Gazouli M. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. Dig Liver Dis 2021;53:574-80. [PMID: 33339749 DOI: 10.1016/j.dld.2020.11.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Schoultz I, Keita ÅV. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function. Cells 2019;8:E193. [PMID: 30813280 DOI: 10.3390/cells8020193] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
17 Hoter A, Naim HY. The Functions and Therapeutic Potential of Heat Shock Proteins in Inflammatory Bowel Disease-An Update. Int J Mol Sci 2019;20:E5331. [PMID: 31717769 DOI: 10.3390/ijms20215331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
18 Swanson KD, Theodorou E, Kokkotou E. Reproducing the human mucosal environment ex vivo: inflammatory bowel disease as a paradigm. Curr Opin Gastroenterol 2018;34:384-91. [PMID: 30188406 DOI: 10.1097/MOG.0000000000000485] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Morilla I, Léger T, Marah A, Pic I, Zaag H, Ogier-Denis E. Singular manifolds of proteomic drivers to model the evolution of inflammatory bowel disease status.Sci Rep. 2020;10:19066. [PMID: 33149233 DOI: 10.1038/s41598-020-76011-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Sgambato D, Gimigliano F, De Musis C, Moretti A, Toro G, Ferrante E, Miranda A, De Mauro D, Romano L, Iolascon G, Romano M. Bone alterations in inflammatory bowel diseases. World J Clin Cases 2019; 7(15): 1908-1925 [PMID: 31423424 DOI: 10.12998/wjcc.v7.i15.1908] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
21 Fakhoury HMA, Kvietys PR, AlKattan W, Anouti FA, Elahi MA, Karras SN, Grant WB. Vitamin D and intestinal homeostasis: Barrier, microbiota, and immune modulation. J Steroid Biochem Mol Biol 2020;200:105663. [PMID: 32194242 DOI: 10.1016/j.jsbmb.2020.105663] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
22 Boldyreva LV, Morozova MV, Saydakova SS, Kozhevnikova EN. Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:11682. [PMID: 34769112 DOI: 10.3390/ijms222111682] [Reference Citation Analysis]
23 Hundhausen C, Schneckmann R, Ostendorf Y, Rimpler J, von Glinski A, Kohlmorgen C, Pasch N, Rolauer L, von Ameln F, Eckermann O, Altschmied J, Ale-Agha N, Haendeler J, Flögel U, Fischer JW, Grandoch M. Endothelial hyaluronan synthase 3 aggravates acute colitis in an experimental model of inflammatory bowel disease. Matrix Biol 2021;102:20-36. [PMID: 34464693 DOI: 10.1016/j.matbio.2021.08.001] [Reference Citation Analysis]
24 Yuan J, Cheng W, Zhang G, Ma Q, Li X, Zhang B, Hu T, Song G. Protective effects of iridoid glycosides on acute colitis via inhibition of the inflammatory response mediated by the STAT3/NF-кB pathway. Int Immunopharmacol 2020;81:106240. [PMID: 32044657 DOI: 10.1016/j.intimp.2020.106240] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
25 Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D, Sun S. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 2020;80:106210. [PMID: 31972425 DOI: 10.1016/j.intimp.2020.106210] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
26 Petito V, Graziani C, Lopetuso LR, Fossati M, Battaglia A, Arena V, Scannone D, Quaranta G, Quagliariello A, Del Chierico F, Putignani L, Masucci L, Sanguinetti M, Sgambato A, Gasbarrini A, Scaldaferri F. Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis. World J Gastroenterol 2019; 25(12): 1465-1477 [PMID: 30948910 DOI: 10.3748/wjg.v25.i12.1465] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Iborra M, Beltrán B, Fernández-Clotet A, Iglesias-Flores E, Navarro P, Rivero M, Gutiérrez A, Sierra-Ausin M, Mesonero F, Ferreiro-Iglesias R, Hinojosa J, Calvet X, Sicilia B, González-Muñoza C, Antolín B, González-Vivo M, Carbajo AY, García-López S, Martín-Cardona A, Surís G, Martin-Arranz MD, de Francisco R, Cañete F, Domènech E, Nos P; GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry. Aliment Pharmacol Ther 2020;52:1017-30. [PMID: 32770851 DOI: 10.1111/apt.15958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Kang EA, Soh H, Park S, Lee HJ, Im JP, Kim JS. Soluble Siglec-9 alleviates intestinal inflammation through inhibition of the NF-κB pathway. Int Immunopharmacol 2020;86:106695. [PMID: 32570035 DOI: 10.1016/j.intimp.2020.106695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
30 Chuang LS, Morrison J, Hsu NY, Labrias PR, Nayar S, Chen E, Villaverde N, Facey JA, Boschetti G, Giri M, Castillo-Martin M, Thin TH, Sharma Y, Chu J, Cho JH. Zebrafish modeling of intestinal injury, bacterial exposures and medications defines epithelial in vivo responses relevant to human inflammatory bowel disease. Dis Model Mech 2019;12:dmm037432. [PMID: 31337664 DOI: 10.1242/dmm.037432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]